These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20691638)

  • 21. A Novel 6-Benzyl Ether Benzoxaborole Is Active against Mycobacterium tuberculosis
    Patel N; O'Malley T; Zhang YK; Xia Y; Sunde B; Flint L; Korkegian A; Ioerger TR; Sacchettini J; Alley MRK; Parish T
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tuberculosis. Part II.
    LoBue PA; Catanzaro A; Dutt AK; Stead W
    Dis Mon; 1997 Apr; 43(4):181-274. PubMed ID: 9146474
    [No Abstract]   [Full Text] [Related]  

  • 23. Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?
    Yew WW; Koh WJ
    Korean J Intern Med; 2016 Jan; 31(1):15-29. PubMed ID: 26767853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Why is long-term therapy required to cure tuberculosis?
    Connolly LE; Edelstein PH; Ramakrishnan L
    PLoS Med; 2007 Mar; 4(3):e120. PubMed ID: 17388672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Primary drug resistance of Mycobacterium tuberculosis in patients with new-onset destructive pulmonary tuberculosis].
    Zinov'ev IP; Esaulova NA; Novikov VG; Kokovikhina IA
    Probl Tuberk Bolezn Legk; 2009; (4):37-9. PubMed ID: 19514452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-tuberculosis drug resistance in Dohuk, Iraq.
    Merza MA; Farnia P; Masjedi MR; Ridell M
    Int J Tuberc Lung Dis; 2010 Sep; 14(9):1213-4. PubMed ID: 20819274
    [No Abstract]   [Full Text] [Related]  

  • 27. Failing a re-treatment regimen does not predict MDR/XDR tuberculosis: is "blind" treatment dangerous?
    Badoum G; Saleri N; Dembélé MS; Ouedraogo M; Pinsi G; Boncoungou K; Bonkoungou V; Birba E; Miotto P; Migliori GB; Cirillo DM; Matteelli A
    Eur Respir J; 2011 May; 37(5):1283-5. PubMed ID: 21532018
    [No Abstract]   [Full Text] [Related]  

  • 28. [Occurence of primary resistance in hospital patients with respiratory tuberculosis].
    Serdarević H; Bogdanović M; Travnik H; Simeonov L
    Tuberkuloza; 1966; 18(1-3):220-7. PubMed ID: 16296090
    [No Abstract]   [Full Text] [Related]  

  • 29. Increasing drug resistance of Mycobacterium tuberculosis in Sinaloa, Mexico, 1997-2005.
    Zazueta-Beltran J; León-Sicairos N; Muro-Amador S; Flores-Gaxiola A; Velazquez-Roman J; Flores-Villaseñor H; Canizalez-Roman A
    Int J Infect Dis; 2011 Apr; 15(4):e272-6. PubMed ID: 21317004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of resistance in multi drug resistant tuberculosis patients.
    Irfan S; Hassan Q; Hasan R
    J Pak Med Assoc; 2006 Sep; 56(9):397-400. PubMed ID: 17091751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pakistan's battle with multi-drug resistant tuberculosis--establishing the ground rules.
    Saleem T; Khalid U
    J Pak Med Assoc; 2012 Jan; 62(1):80. PubMed ID: 22352115
    [No Abstract]   [Full Text] [Related]  

  • 32. The early bactericidal activity of antituberculosis drugs.
    Diacon AH; Donald PR
    Expert Rev Anti Infect Ther; 2014 Feb; 12(2):223-37. PubMed ID: 24392698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Multidrug-resistant tuberculosis in Romania].
    Stoicescu IP; Didilescu C; Bercea O
    Pneumoftiziologia; 1997; 46(3):161-78. PubMed ID: 9654954
    [No Abstract]   [Full Text] [Related]  

  • 34. Drug resistance to the first line of antitubercular regimen (a preliminary report).
    Varaiya A; Gogate A
    Indian J Public Health; 1998; 42(4):126-30. PubMed ID: 10389525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [In vitro activities of rifabutine and rifampicin against various mycobacteria, especially Mycobacterium tuberculosis and Mycobacterium avium complex].
    Saito H; Sato K; Tomioka H
    Kekkaku; 1988 Mar; 63(3):167-72. PubMed ID: 2836649
    [No Abstract]   [Full Text] [Related]  

  • 36. [Sparfloxacin in combined therapy for pulmonary tuberculosis].
    Sokolova GB; Khaĭmenova TIu; Lazareva IaV; Khaĭmenov AIa
    Antibiot Khimioter; 2008; 53(5-6):21-7. PubMed ID: 19069178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [M. tuberculosis drug resistance and occurrence in patients with pulmonary tuberculosis].
    Novozhylova IO
    Lik Sprava; 2003 Dec; (8):16-20. PubMed ID: 14964999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimycobacterial activity of Citrullus colocynthis (L.) Schrad. against drug sensitive and drug resistant Mycobacterium tuberculosis and MOTT clinical isolates.
    Mehta A; Srivastva G; Kachhwaha S; Sharma M; Kothari SL
    J Ethnopharmacol; 2013 Aug; 149(1):195-200. PubMed ID: 23816500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proficiency testing of first- and second-line anti-tuberculosis drugs in Italy.
    Fattorini L; Migliori GB; Cassone A; Mustazzolu A; Piccaro G; Filippini P; Cirillo DM; Borroni E;
    Eur Respir J; 2012 May; 39(5):1263-6. PubMed ID: 22547735
    [No Abstract]   [Full Text] [Related]  

  • 40. Incidence of multidrug-resistant tuberculosis in urban and rural India and implications for prevention.
    Almeida D; Rodrigues C; Udwadia ZF; Lalvani A; Gothi GD; Mehta P; Mehta A
    Clin Infect Dis; 2003 Jun; 36(12):e152-4. PubMed ID: 12802779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.